Additionally, a broader set of 60 glioma-related targets specific to CHR was identified (Figure 6B); this gene set includes multiple multidrug resistance-associated transporters (ABCB1, ABCC1, ABCG2), cyclin-dependent kinases (CDK1, CDK6), matrix metalloproteinases (MMP2, MMP9, MMP12), inflammatory mediators (NOS2, NOX4), and genes associated with glioma stemness or progression (APP, MAPT, IGF1R, TERT). The gene discussed is MMP12; the disease is central nervous system cancer.